Science 37

Science 37 specializes in decentralized and hybrid clinical trial solutions, enabling remote patient participation through its proprietary technology platforms. It has successfully supported fully virtual and hybrid trials for major pharmaceutical companies, improving patient access and accelerating timelines for diverse therapeutic areas including infectious diseases, mental health disorders like MDD, dermatology, neurology, and metabolic diseases.

The company has demonstrated the feasibility of site-less randomized controlled trials at scale—such as the first interventional virtual RCT with AOBiome Therapeutics—and continues to expand its reach globally through partnerships with pharma leaders like Novartis, Sanofi, Genentech/Otsuka Pharmaceutical.

In March 2024 it was acquired by eMed LLC to further enhance telehealth-enabled diagnostics and decentralized research capabilities.

No direct clinical results are reported since it does not sponsor drugs or devices.